Rationale and Design of EMPOWER, a Pragmatic Randomized Trial of Automated Hovering in Patients With Congestive Heart Failure

被引:10
|
作者
Mehta, Shivan J. [1 ,2 ,3 ]
Volpp, Kevin G. [1 ,2 ,3 ]
Asch, David A. [1 ,2 ,3 ]
Goldberg, Lee R. [1 ,2 ]
Russell, Louise B. [1 ,2 ]
Norton, Laurie A. [1 ,2 ]
Iannotte, Lauren G. [1 ,2 ]
Troxel, Andrea B. [4 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Dept Hlth Policy & Med Eth, Philadelphia, PA 19104 USA
[3] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA
[4] NYU, Sch Med, Dept Populat Hlth, Div Biostat, New York, NY USA
来源
关键词
disease management; health care cost; heart failure; morbidity; mortality; HEALTH; HOSPITALIZATION; MANAGEMENT; ADHERENCE; OUTCOMES; RISK; MORTALITY; PATTERNS; SURVIVAL; MODEL;
D O I
10.1161/CIRCOUTCOMES.118.005126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Congestive heart failure is a major cause of morbidity, mortality, and cost. Disease management programs have shown promise but lack firm evidence of effectiveness and scalability. We describe the motivation, design, and planned analyses of EMPOWER (Electronic Monitoring of Patients Offers Ways to Enhance Recovery), a randomized clinical trial of an innovative intervention incorporating behavioral economic principles with remote monitoring technology embedded within a healthcare system. METHODS AND RESULTS: EMPOWER is an ongoing, pragmatic, randomized clinical trial comparing usual care to an automated hovering intervention that includes patient-level incentives for daily weight monitoring and diuretic adherence combined with automated feedback into the clinical care pathway, enabling real-time response to concerning clinical symptoms. Identification of eligible patients began in May 2016, and implementation of the intervention is feasible. Trial processes are embedded into existing clinical pathways. The primary outcome is time to readmission for any cause. Cost-effectiveness analyses are planned to evaluate the healthcare costs and health outcomes of the approach. CONCLUSIONS: The EMPOWER trial incorporates leading-edge approaches in human motivation, derived from behavioral economics, with contemporary technology to provide scale and exception handling at low cost. The trial is also implemented within the naturalized environment of a health system, as much as possible taking advantage of the existing journeys of patients and workflows of clinicians. A goal of this pragmatic design is to limit resource utilization and also to test an intervention that would need minimal modification to be translated from research into a new way of practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] THE RATIONALE OF THE TREATMENT OF CONGESTIVE HEART-FAILURE
    TELERMAN, M
    DECOODT, P
    PEPERSTRAETE, B
    ACTA CARDIOLOGICA, 1982, : 77 - 83
  • [22] Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial
    Peter M Wayne
    Julie E Buring
    Roger B Davis
    Ellen M Connors
    Paolo Bonato
    Benjamin Patritti
    Mary Fischer
    Gloria Y Yeh
    Calvin J Cohen
    Danette Carroll
    Douglas P Kiel
    BMC Musculoskeletal Disorders, 11
  • [23] Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial
    Wayne, Peter M.
    Buring, Julie E.
    Davis, Roger B.
    Connors, Ellen M.
    Bonato, Paolo
    Patritti, Benjamin
    Fischer, Mary
    Yeh, Gloria Y.
    Cohen, Calvin J.
    Carroll, Danette
    Kiel, Douglas P.
    BMC MUSCULOSKELETAL DISORDERS, 2010, 11
  • [24] High-Intensity Small Muscle Mass Training in Patients With Heart Failure: Rationale and Design of a Randomized Controlled Trial
    Louis, Menaka
    Hwang, Rita
    Sabapathy, Surendran
    Roberts, Llion Arwyn
    Morris, Norman Rolston
    PHYSICAL THERAPY, 2024, 104 (01):
  • [25] Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design
    Loeb, Mark
    Dokainish, Hisham
    Dans, Antonio
    Palileo-Villanueva, Lia M.
    Roy, Ambuj
    Karaye, Kamilu
    Zhu, Jun
    Liang, Yan
    Goma, Fastone
    Damasceno, Albertino
    AlHabib, Khalid F.
    Yonga, Gerald
    Mondo, Charles
    Almahmeed, Wael
    Al Mulla, Arif
    Yusuf, Salim
    AMERICAN HEART JOURNAL, 2019, 212 : 36 - 44
  • [26] Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial
    Tanaka, Atsushi
    Inoue, Teruo
    Kitakaze, Masafumi
    Oyama, Jun-ichi
    Sata, Masataka
    Taguchi, Isao
    Shimizu, Wataru
    Watada, Hirotaka
    Tomiyama, Hirofumi
    Ako, Junya
    Sakata, Yasushi
    Anzai, Toshihisa
    Uematsu, Masaaki
    Suzuki, Makoto
    Eguchi, Kazuo
    Yamashina, Akira
    Saito, Yoshihiko
    Sato, Yasunori
    Ueda, Shinichiro
    Murohara, Toyoaki
    Node, Koichi
    CARDIOVASCULAR DIABETOLOGY, 2016, 15
  • [27] Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial
    Atsushi Tanaka
    Teruo Inoue
    Masafumi Kitakaze
    Jun-ichi Oyama
    Masataka Sata
    Isao Taguchi
    Wataru Shimizu
    Hirotaka Watada
    Hirofumi Tomiyama
    Junya Ako
    Yasushi Sakata
    Toshihisa Anzai
    Masaaki Uematsu
    Makoto Suzuki
    Kazuo Eguchi
    Akira Yamashina
    Yoshihiko Saito
    Yasunori Sato
    Shinichiro Ueda
    Toyoaki Murohara
    Koichi Node
    Cardiovascular Diabetology, 15
  • [28] Rationale, design, and methods for a pivotal randomized clinical trial of continuous aortic flow augmentation in patients with exacerbation of heart failure: The MOMENTUM trial
    Greenberg, Barry
    Czerska, Barbara
    Abraham, William T.
    Neaton, James D.
    Delgado, Reynolds M.
    Mather, Paul
    Bourge, Robert
    Parker, Irene C.
    Konstam, Marvin A.
    JOURNAL OF CARDIAC FAILURE, 2007, 13 (09) : 715 - 721
  • [29] Resynchronization/defibrillation for ambulatory heart failure trial: rationale and trial design
    Tang, Anthony S.
    Wells, George A.
    Arnold, Malcolm
    Connolly, Stuart
    Hohnloser, Stefan
    Nichol, Graham
    Rouleau, Jean
    Sheldon, Robert
    Talajic, Mario
    CURRENT OPINION IN CARDIOLOGY, 2009, 24 (01) : 1 - 8
  • [30] Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure
    Tavazzi, L
    Tognoni, G
    Franzosi, MG
    Latini, R
    Maggioni, AP
    Marchioli, R
    Nicolosi, GL
    Porcu, M
    EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (05) : 635 - 641